

# CONTENTS

|   |           |
|---|-----------|
| <b>SUMMARY</b>  | <b>1</b>  |
| <b>INTRODUCTION</b>   | <b>5</b>  |
| <b>OBJECTIVES</b>   | <b>7</b>  |
| <b>METHODOLOGY</b>  | <b>9</b>  |
| <b>DEFINITIONS</b>  | <b>11</b> |
| <b>RESULTS</b>  | <b>13</b> |
| <b>1. General questions relating to portfolio management</b>  | <b>15</b> |
| 1.1a Frequency of review of the development portfolio   | 17        |
| 1.1b Personnel involved in the development portfolio review   | 18        |
| 1.2 Number of years for which portfolio management systems has been in place                                      | 19        |
| 1.3 Strategy for company portfolio management of development projects   | 20        |
| 1.4 Satisfaction with present portfolio management system   | 21        |
| 1.5a Prioritisation of projects within the development portfolio  | 22        |
| 1.5b Criteria used for prioritisation   | 23        |
| 1.6a Use of attrition data in portfolio management  | 24        |
| 1.6b Source of attrition data used in portfolio management  | 25        |
| <b>2. Procedures used in portfolio management</b>   | <b>27</b> |
| 2.1a Procedures used in making the decision to start pre-clinical development to support administration to humans | 29        |
| 2.1b Procedures used in making the decision to administer to humans   | 30        |
| 2.1c Procedures used in making the decision to administer to patients   | 31        |
| 2.1d Procedures used in making the decision to start full scale development for launch                            | 32        |
| 2.1e Procedures used in making the decision to submit/register  | 33        |
| 2.2 Is the same portfolio management system used for all projects irrespective of type of compound?               | 34        |
| <b>3. Information used in portfolio management</b>  | <b>35</b> |
| 3.1a Information used in decision to start pre-clinical development to support administration to humans           | 37        |
| 3.1b Information used in decision to administer to humans   | 38        |
| 3.1c Information used in decision to administer to patients   | 39        |
| 3.1d Information used in decision to start full scale development for launch                                      | 40        |
| 3.1e Information used in decision to submit/register  | 40        |
| 3.2 Time taken to collate the information required for last development portfolio review                          | 42        |
| <b>4. Other aspects of portfolio management</b>   | <b>43</b> |
| 4.1 Is there an ideal or target number of NMEs, line extension and other projects in the development portfolio?   | 45        |
| 4.2 Validation of portfolio management system for development projects  |           |

|           |   |           |
|-----------|---|-----------|
| 4.3       | Issues in relation to portfolio management that need to be addressed                  | 47        |
| 4.4       | Ways to resolve issues of concern   | 48        |
| 4.5       | Issues that are suitable for discussion at future CMR International industry meetings | 49        |
| <b>5.</b> | <b>CMR International Discussion Meeting</b>   | <b>51</b> |
|           | <b>DISCUSSION</b>   | <b>53</b> |
|           | <b>FUTURE WORK</b>  | <b>57</b> |
|           | <b>ACKNOWLEDGEMENT</b>  | <b>59</b> |
|           | <b>REFERENCES</b>   | <b>61</b> |
|           | <b>APPENDIX 1:</b> Pharmaceutical companies invited to participate                    | <b>65</b> |
|           | <b>APPENDIX 2:</b> Questionnaire used in survey                                       | <b>67</b> |
|           | <b>APPENDIX 3:</b> Programme for CMR industry discussion meeting                      | <b>69</b> |